Morgan E Grams1, Liang Li2, Tom H Greene3, Adrienne Tin4, Yingying Sang4, W H Linda Kao5, Michael S Lipkowitz6, Jackson T Wright7, Alex R Chang8, Brad C Astor9, Lawrence J Appel10. 1. Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD. Electronic address: mgrams2@jhmi.edu. 2. University of Texas MD Anderson Cancer Center, Houston, TX. 3. Division of Clinical Epidemiology, University of Utah School of Medicine, Salt Lake City, UT. 4. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD. 5. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD. 6. Division of Nephrology, Georgetown University School of Medicine, Washington, DC. 7. Department of Medicine, Case Western Reserve University, Cleveland, OH. 8. Division of Nephrology, Geisinger Health System, Danville, PA. 9. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI; Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI. 10. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD; University of Texas MD Anderson Cancer Center, Houston, TX; Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Planning for renal replacement therapy, such as referral for arteriovenous fistula placement and transplantation, often is guided by level of estimated glomerular filtration rate (eGFR). The use of risk equations might enable more accurate estimation of time to end-stage renal disease (ESRD), thus improving patient care. STUDY DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 1,094 participants in the African American Study of Kidney Disease and Hypertension (AASK) cohort. PREDICTOR: Age, sex, urine protein-creatinine ratio ≥ 1g/g, APOL1 high-risk status, and 3-year antecedent eGFR decline. OUTCOME: Cumulative incidence of ESRD from 5 different starting points: eGFR of 30 and 15mL/min/1.73m(2) and 1-year ESRD risk of 5%, 10%, and 20%, estimated by a published 4-variable kidney failure risk equation. RESULTS:566 participants developed eGFR of 30mL/min/1.73m(2), 244 developed eGFR of 15mL/min/1.73m(2), and 437, 336, and 259 developed1-year ESRD risks of 5%, 10%, and 20%, respectively. The 1-year cumulative incidence of ESRD was 4.3% from eGFR of 30mL/min/1.73m(2), 49.0% from eGFR of 15mL/min/1.73m(2), 6.7% from 5% ESRD risk, 15.0% from 10% ESRD risk, and 29% from 20% ESRD risk. From eGFR of 30mL/min/1.73m(2), there were several risk factors that predicted ESRD risk. From eGFR of 15mL/min/1.73m(2), only level of proteinuria did; median time to ESRD was 9 and 19 months in those with higher and lower proteinuria, respectively. Median times were less variable from corresponding ESRD risk thresholds. For example, median times to ESRD from 20% ESRD risk were 22 and 25 months among those with higher and lower proteinuria, respectively. LIMITATIONS: Relatively homogeneous population of African Americans with hypertensive kidney disease. CONCLUSIONS: Results of the present study suggest the potential benefit of incorporating kidney failure risk equations into clinical care, with selection of a specific threshold guided by its intended use.
RCT Entities:
BACKGROUND: Planning for renal replacement therapy, such as referral for arteriovenous fistula placement and transplantation, often is guided by level of estimated glomerular filtration rate (eGFR). The use of risk equations might enable more accurate estimation of time to end-stage renal disease (ESRD), thus improving patient care. STUDY DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 1,094 participants in the African American Study of Kidney Disease and Hypertension (AASK) cohort. PREDICTOR: Age, sex, urine protein-creatinine ratio ≥ 1g/g, APOL1 high-risk status, and 3-year antecedent eGFR decline. OUTCOME: Cumulative incidence of ESRD from 5 different starting points: eGFR of 30 and 15mL/min/1.73m(2) and 1-year ESRD risk of 5%, 10%, and 20%, estimated by a published 4-variable kidney failure risk equation. RESULTS: 566 participants developed eGFR of 30mL/min/1.73m(2), 244 developed eGFR of 15mL/min/1.73m(2), and 437, 336, and 259 developed 1-year ESRD risks of 5%, 10%, and 20%, respectively. The 1-year cumulative incidence of ESRD was 4.3% from eGFR of 30mL/min/1.73m(2), 49.0% from eGFR of 15mL/min/1.73m(2), 6.7% from 5% ESRD risk, 15.0% from 10% ESRD risk, and 29% from 20% ESRD risk. From eGFR of 30mL/min/1.73m(2), there were several risk factors that predicted ESRD risk. From eGFR of 15mL/min/1.73m(2), only level of proteinuria did; median time to ESRD was 9 and 19 months in those with higher and lower proteinuria, respectively. Median times were less variable from corresponding ESRD risk thresholds. For example, median times to ESRD from 20% ESRD risk were 22 and 25 months among those with higher and lower proteinuria, respectively. LIMITATIONS: Relatively homogeneous population of African Americans with hypertensive kidney disease. CONCLUSIONS: Results of the present study suggest the potential benefit of incorporating kidney failure risk equations into clinical care, with selection of a specific threshold guided by its intended use.
Authors: Ann M O'Hare; Adam Batten; Nilka Ríos Burrows; Meda E Pavkov; Leslie Taylor; Indra Gupta; Jeff Todd-Stenberg; Charles Maynard; Rudolph A Rodriguez; Fliss E M Murtagh; Eric B Larson; Desmond E Williams Journal: Am J Kidney Dis Date: 2012-02-04 Impact factor: 8.860
Authors: Liang Li; Brad C Astor; Julia Lewis; Bo Hu; Lawrence J Appel; Michael S Lipkowitz; Robert D Toto; Xuelei Wang; Jackson T Wright; Tom H Greene Journal: Am J Kidney Dis Date: 2012-01-26 Impact factor: 8.860
Authors: Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao Journal: J Am Soc Nephrol Date: 2013-06-13 Impact factor: 10.121
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Tahira P Alves; Xuelei Wang; Jackson T Wright; Lawrence J Appel; Tom Greene; Keith Norris; Julia Lewis Journal: J Am Soc Nephrol Date: 2010-07-22 Impact factor: 10.121
Authors: Zahra Kanji; Camille E Powe; Julia B Wenger; Chunmei Huang; Elizabeth Ankers; Dorothy A Sullivan; Gina Collerone; Neil R Powe; Marcello Tonelli; Ishir Bhan; Andrea J Bernhardy; Salvatore Dibartolo; David Friedman; Giulio Genovese; Martin R Pollak; Ravi Thadhani Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Morgan E Grams; Josef Coresh; Dorry L Segev; Lauren M Kucirka; Hocine Tighiouart; Mark J Sarnak Journal: Clin J Am Soc Nephrol Date: 2012-08-02 Impact factor: 8.237
Authors: Navdeep Tangri; Morgan E Grams; Andrew S Levey; Josef Coresh; Lawrence J Appel; Brad C Astor; Gabriel Chodick; Allan J Collins; Ognjenka Djurdjev; C Raina Elley; Marie Evans; Amit X Garg; Stein I Hallan; Lesley A Inker; Sadayoshi Ito; Sun Ha Jee; Csaba P Kovesdy; Florian Kronenberg; Hiddo J Lambers Heerspink; Angharad Marks; Girish N Nadkarni; Sankar D Navaneethan; Robert G Nelson; Stephanie Titze; Mark J Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Morgan E Grams; Wei Yang; Casey M Rebholz; Xue Wang; Anna C Porter; Lesley A Inker; Edward Horwitz; James H Sondheimer; L Lee Hamm; Jiang He; Matthew R Weir; Bernard G Jaar; Tariq Shafi; Lawrence J Appel; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2017-03-30 Impact factor: 8.860
Authors: Erica Winnicki; Charles E McCulloch; Mark M Mitsnefes; Susan L Furth; Bradley A Warady; Elaine Ku Journal: JAMA Pediatr Date: 2018-02-01 Impact factor: 16.193
Authors: Casey M Rebholz; Josef Coresh; Shoshana H Ballew; Blaithin McMahon; Seamus P Whelton; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2015-03-12 Impact factor: 8.860
Authors: Felipe S Naranjo; Yingying Sang; Shoshana H Ballew; Nikita Stempniewicz; Stephan C Dunning; Andrew S Levey; Josef Coresh; Morgan E Grams Journal: Kidney360 Date: 2021-01-06
Authors: Teresa K Chen; Adrienne Tin; Carmen A Peralta; Lawrence J Appel; Michael J Choi; Michael S Lipkowitz; Cheryl A Winkler; Michelle M Estrella Journal: Clin J Am Soc Nephrol Date: 2017-10-19 Impact factor: 8.237
Authors: Michael F Schneider; Alvaro Muñoz; Elaine Ku; Bradley A Warady; Susan L Furth; George J Schwartz Journal: Am J Kidney Dis Date: 2020-09-06 Impact factor: 8.860